Abstract.
Radiolabelled peptides are an emerging class of radiopharmaceuticals that share chemical and biological properties. From the chemical point of view they have a poly-amino acid structure varying from 3 to more that 200 amino acids, and they are labelled with different isotopes directly or by a linker. Biologically, they bind to specific cell membrane receptors, thus providing in vivo histopathological information for diagnostic purposes, therapy follow-up or targeted radiotherapy. This paper reviews most of the radiolabelled peptides that have been tested in animals and humans in the fields of oncology, neurology, cardiology, inflammation/infection, atherosclerosis and thrombosis. A new classification is also proposed for peptides targeting tumour cells based on the biological function of target receptors. These tailored radiopharmaceuticals are the basis of the new era of "molecular nuclear medicine".
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
An erratum to this article is available at http://dx.doi.org/10.1007/s00259-001-0663-7.
Rights and permissions
About this article
Cite this article
Signore, .A., Annovazzi, .A., Chianelli, .M. et al. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 28, 1555–1565 (2001). https://doi.org/10.1007/s002590100583
Issue Date:
DOI: https://doi.org/10.1007/s002590100583